ExodusPoint Capital Management’s Matinas BioPharma MTNB Stock Holding History

ExodusPoint Capital Management’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-920	Closed	-$23K	–	1999
2022 Q4	$23K	Buy	+920	New	+$30.6K	﹤0.01%	1566
2021 Q2	–	Sell	-7,613	Closed	-$400K	–	2647
2021 Q1	$400K	Sell	7,613 -4,946	-39%	-$332K	0.01%	1503
2020 Q4	$854K	Buy	+12,559	New	+$582K	0.01%	942
2020 Q3	–	Sell	-422	Closed	-$16K	–	2060
2020 Q2	$16K	Sell	422 -6,061	-93%	-$232K	﹤0.01%	1712
2020 Q1	$195K	Sell	6,483 -2,986	-32%	-$180K	0.01%	800
2019 Q4	$1.07M	Buy	+9,469	New	+$549K	0.02%	525
2019 Q2	–	Sell	-764	Closed	-$42K	–	1258
2019 Q1	$42K	Buy	+764	New	+$41.1K	﹤0.01%	644

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NRS

Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

SCA

STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

ExodusPoint Capital Management's MTNB Position: Q1 2023 in Review

ExodusPoint Capital Management sold out of Matinas BioPharma (MTNB) in Q1 2023, closing a stake of 920 shares — an estimated $23K sold.

ExodusPoint Capital Management first reported a position in MTNB in Q1 2019 and held it in 7 quarters. The position peaked at $1.07M in Q4 2019. 50 funds tracked by Wall St. Rank hold MTNB as of Q1 2023.

ExodusPoint Capital Management reported no remaining Matinas BioPharma position as of Q1 2023 after selling out during the quarter.
ExodusPoint Capital Management sold 920 Matinas BioPharma shares in Q1 2023, an estimated $23K.
ExodusPoint Capital Management first reported a position in Matinas BioPharma in Q1 2019 and held it in 7 quarters.
ExodusPoint Capital Management's Matinas BioPharma position peaked at $1.07M in Q4 2019.
50 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2023.

Based on ExodusPoint Capital Management's 13F filing for Q1 2023, filed 11 May 2023.